Literature DB >> 11771743

Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease.

B Balcz1, L Kirchner, N Cairns, M Fountoulakis, G Lubec.   

Abstract

Oxidative stress is considered to be crucial in the pathogenesis of Alzheimer's disease-like neurodegeneration. An elevation of carbonyl compounds that are biomarkers of and leading to oxidative stress has been demonstrated in Down Syndrome (DS) and Alzheimer's Disease (AD) brains and seems to be the result of a multifactorial process. Carbonyls, which are cytotoxic metabolic intermediates, are detoxified by either oxidation catalyzed by aldehyde dehydrogenase (ALDH), or by reduction to their corresponding alcohols by carbonyl reductase (CBR) and/or alcohol dehydrogenase (ADH). We quantified protein levels of CBR and its agonist/antagonist ADH using 2D gel electrophoresis with subsequent MALDI-identification and specific software in several brain regions of DS as well as AD patients and compared them to levels of CBR and ADH in brains of controls. Protein levels of both enzymes were increased in several brain regions because of enzyme induction by elevated carbonyls in DS and AD. Increased CBR in DS (trisomy 21) may be due to a gene dosage effect as the gene encoding CBR has been mapped to chromosome 21. These findings may confirm the proposed increase of reactive carbonyls in the brain thus supporting the involvement of oxidative stress and contribute to the understanding of carbonyl handling in brain of both neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11771743     DOI: 10.1007/978-3-7091-6262-0_15

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  17 in total

1.  Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome.

Authors:  James L Kalabus; Carrie C Sanborn; Raqeeb G Jamil; Qiuying Cheng; Javier G Blanco
Journal:  Drug Metab Dispos       Date:  2010-08-20       Impact factor: 3.922

Review 2.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

3.  Design, synthesis, and ex vivo evaluation of a selective inhibitor for retinaldehyde dehydrogenase enzymes.

Authors:  Angelica R Harper; Anh T Le; Timothy Mather; Anthony Burgett; William Berry; Jody A Summers
Journal:  Bioorg Med Chem       Date:  2018-10-24       Impact factor: 3.641

4.  Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) × PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age.

Authors:  Rukhsana Sultana; Renã A S Robinson; Fabio Di Domenico; Hafiz Mohmmad Abdul; Daret K St Clair; William R Markesbery; Jian Cai; William M Pierce; D Allan Butterfield
Journal:  J Proteomics       Date:  2011-06-25       Impact factor: 4.044

Review 5.  Neurodegenerative mutants in Drosophila: a means to identify genes and mechanisms involved in human diseases?

Authors:  Doris Kretzschmar
Journal:  Invert Neurosci       Date:  2005-10-24

Review 6.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

Review 7.  4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies.

Authors:  Marzia Perluigi; Raffaella Coccia; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-02-15       Impact factor: 8.401

Review 8.  Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.

Authors:  Marzia Perluigi; Fabio Di Domenico; D Allan Buttterfield
Journal:  Proteomics Clin Appl       Date:  2014-02       Impact factor: 3.494

Review 9.  HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.

Authors:  Eugenio Barone; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2016-11-10       Impact factor: 7.376

10.  First evidence of overlaps between HIV-Associated Dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia.

Authors:  Li Zhou; Eve Diefenbach; Ben Crossett; Sieu L Tran; Thomas Ng; Helen Rizos; Rejane Rua; Bin Wang; Amit Kapur; Kaushal Gandhi; Bruce J Brew; Nitin K Saksena
Journal:  Mol Neurodegener       Date:  2010-06-24       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.